Related Experiment Video
Updated: Jul 6, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
GLP-1 receptor agonists in pediatric obesity.
Martina Abodi1, Carlo V Agostoni2, Alessandra Mazzocchi3
1Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy; ONFoods-Research and Innovation Network on Food and Nutrition Sustainability, Safety and Security-Working ON Foods, 20122, Milan, Italy; Infertility Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for pediatric obesity management, aiding weight loss and improving cardiometabolic health. Further research is needed on long-term safety and integration with lifestyle interventions.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
- Public Health
Background:
- Childhood obesity is a growing epidemic with serious health consequences.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective for adult obesity and are being explored for pediatric use.
- GLP-1RAs offer potential benefits beyond weight loss, including cardiometabolic and kidney improvements.
Purpose of the Study:
- To review the current evidence on GLP-1RAs for pediatric obesity management.
- To discuss the efficacy, safety, and implementation challenges of GLP-1RAs in adolescents.
- To highlight the need for integrated, family-centered care models.
Main Methods:
- Review of clinical trials and scientific literature on GLP-1RAs in pediatric populations.
- Analysis of efficacy data for weight loss and cardiometabolic parameters.
- Assessment of safety profiles, including adverse events and impact on growth.
Main Results:
- Liraglutide and semaglutide demonstrate efficacy in adolescents (≥12 years), with FDA and EMA approvals.
- Common side effects are gastrointestinal; no consistent impact on growth or puberty reported.
- Ongoing trials explore combination therapies and use alongside bariatric surgery.
Conclusions:
- GLP-1RAs represent a significant advancement in pediatric obesity pharmacotherapy.
- Addressing psychosocial factors, access disparities, and integrating lifestyle interventions are crucial.
- Long-term data and multidisciplinary approaches are essential for optimal care models.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...